A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples